Free Trial

NeoGenomics (NEO) Financials

NeoGenomics logo
$10.27 +0.18 (+1.78%)
Closing price 04:00 PM Eastern
Extended Trading
$9.71 -0.56 (-5.44%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for NeoGenomics

Annual Income Statements for NeoGenomics

This table shows NeoGenomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
1.13 -2.66 -31 -11 6.09 8.01 4.17 -8.35 -144 -88 -79
Consolidated Net Income / (Loss)
1.13 -2.54 -6.14 -0.40 2.64 8.01 4.17 -8.35 -144 -88 -79
Net Income / (Loss) Continuing Operations
1.13 -2.54 -6.14 -0.40 2.64 8.01 4.17 -8.35 -144 -88 -79
Total Pre-Tax Income
1.29 -4.49 -7.84 -2.65 3.82 3.65 -14 -15 -159 -97 -81
Total Operating Income
2.22 -5.64 2.16 2.90 10 13 -14 -119 -158 -108 -92
Total Gross Profit
41 44 98 102 127 197 186 187 188 245 290
Total Revenue
87 100 232 240 277 409 444 484 510 592 661
Operating Revenue
87 100 232 240 277 409 444 484 510 592 661
Total Cost of Revenue
46 56 134 138 149 212 259 297 322 347 370
Operating Cost of Revenue
46 56 134 138 149 212 259 297 322 347 370
Total Operating Expenses
38 49 96 99 117 184 200 306 346 352 382
Selling, General & Admin Expense
24 34 64 70 85 128 144 221 243 243 260
Marketing Expense
12 12 24 24 29 47 48 63 67 71 85
Research & Development Expense
2.69 4.20 4.65 3.64 3.00 8.49 8.23 22 30 27 31
Restructuring Charge
- - - - - - 0.00 0.00 4.52 11 6.66
Total Other Income / (Expense), net
-0.93 1.15 -10.00 -5.55 -6.22 -9.36 -0.06 104 -1.72 11 11
Interest Expense
0.99 0.85 10.00 5.54 6.23 4.73 12 8.22 7.58 6.91 6.62
Interest & Investment Income
- - - - - - - 3.14 6.08 17 18
Other Income / (Expense), net
0.06 2.00 0.00 -0.01 0.01 -4.63 12 109 -0.21 0.64 -0.38
Income Tax Expense
0.16 -1.95 -1.70 -2.25 1.18 -4.36 -18 -6.73 -15 -9.13 -1.95
Basic Earnings per Share
$0.02 ($0.04) ($0.40) ($0.14) $0.07 $0.08 - - ($1.16) ($0.70) ($0.62)
Weighted Average Basic Shares Outstanding
53.48M 60.53M 77.54M 79.43M 85.62M 100.47M 108.58M 119.96M 124.22M 125.50M 126.66M
Diluted Earnings per Share
$0.02 ($0.04) ($0.40) ($0.14) $0.07 $0.08 - - ($1.16) ($0.70) ($0.62)
Weighted Average Diluted Shares Outstanding
56.02M 60.53M 77.54M 79.43M 91.57M 103.62M 111.79M 119.96M 124.22M 125.50M 126.66M
Weighted Average Basic & Diluted Shares Outstanding
56.60M 66.40M 78.82M 80.51M 94.57M 104.83M 116.94M 124.03M 127.46M 127.61M 128.46M

Quarterly Income Statements for NeoGenomics

This table shows NeoGenomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-37 -23 -31 -24 -19 -14 -27 -19 -18 -15
Consolidated Net Income / (Loss)
-37 -23 -31 -24 -19 -14 -27 -19 -18 -15
Net Income / (Loss) Continuing Operations
-37 -23 -31 -24 -19 -14 -27 -19 -18 -15
Total Pre-Tax Income
-40 -26 -34 -27 -21 -15 -28 -19 -18 -16
Total Operating Income
-40 -26 -35 -30 -24 -19 -31 -22 -21 -18
Total Gross Profit
49 57 55 60 62 68 65 72 75 77
Total Revenue
129 139 137 147 152 156 156 165 168 172
Operating Revenue
129 139 137 147 152 156 156 165 168 172
Total Cost of Revenue
80 82 82 87 90 88 91 92 93 95
Operating Cost of Revenue
80 82 82 87 90 88 91 92 93 95
Total Operating Expenses
88 83 90 90 87 86 96 94 96 96
Selling, General & Admin Expense
64 55 62 60 61 60 66 63 67 64
Marketing Expense
17 17 16 19 18 18 20 22 20 22
Research & Development Expense
7.31 6.68 7.40 7.50 5.29 7.13 7.62 7.89 7.68 7.97
Restructuring Charge
0.00 4.52 4.68 3.07 2.13 1.21 2.40 1.54 1.01 1.71
Total Other Income / (Expense), net
-0.11 0.86 1.35 3.25 2.74 3.29 2.89 2.92 3.35 2.27
Interest Expense
0.14 5.22 1.76 1.78 1.69 1.68 1.69 1.67 1.64 1.62
Interest & Investment Income
- - 3.22 4.31 4.53 4.85 4.83 4.59 4.67 4.33
Other Income / (Expense), net
0.03 -0.00 -0.11 0.73 -0.10 0.12 -0.26 -0.00 0.32 -0.43
Income Tax Expense
-2.77 -2.84 -2.93 -2.31 -2.94 -0.96 -0.62 -0.38 -0.15 -0.80
Weighted Average Basic Shares Outstanding
124.43M 124.22M 125.03M 125.36M 125.69M 125.50M 126.11M 126.41M 126.95M 126.66M
Weighted Average Diluted Shares Outstanding
124.43M 124.22M 125.03M 125.36M 125.69M 125.50M 126.11M 126.41M 126.95M 126.66M
Weighted Average Basic & Diluted Shares Outstanding
126.30M 127.46M 127.58M 127.55M 127.47M 127.61M 127.71M 128.16M 128.36M 128.46M

Annual Cash Flow Statements for NeoGenomics

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
29 -10 -11 0.30 -3.01 163 78 66 -54 79 25
Net Cash From Operating Activities
9.45 6.39 21 18 45 23 1.46 -27 -66 -1.95 7.02
Net Cash From Continuing Operating Activities
9.45 6.39 21 18 45 23 1.46 -27 -66 -1.95 7.02
Net Income / (Loss) Continuing Operations
1.13 -2.54 -6.14 -0.40 2.64 8.01 4.17 -8.35 -144 -88 -79
Consolidated Net Income / (Loss)
1.13 -2.54 -6.14 -0.40 2.64 8.01 4.17 -8.35 -144 -88 -79
Depreciation Expense
5.35 6.73 16 16 16 20 26 30 35 37 39
Amortization Expense
0.36 0.41 11 7.44 6.47 10 14 26 37 38 36
Non-Cash Adjustments To Reconcile Net Income
3.13 3.73 10 7.75 7.36 17 -6.35 -84 36 28 37
Changes in Operating Assets and Liabilities, net
-0.52 -1.95 -9.09 -12 13 -32 -37 10 -30 -18 -26
Net Cash From Investing Activities
-9.60 -75 -6.50 -14 -140 -20 -159 -632 0.52 77 13
Net Cash From Continuing Investing Activities
-9.60 -75 -6.50 -14 -140 -20 -159 -632 0.52 77 13
Purchase of Property, Plant & Equipment
-3.77 -2.22 -7.54 -14 -14 -20 -29 -64 -31 -29 -41
Purchase of Investments
- - - - 0.00 0.00 -99 -212 -98 -6.76 0.00
Sale of Property, Plant & Equipment
- - - - - - 0.00 0.00 12 0.00 0.00
Sale and/or Maturity of Investments
- - - - 0.00 0.00 5.36 63 117 112 54
Net Cash From Financing Activities
29 58 -26 -4.10 92 159 236 725 12 4.55 4.65
Net Cash From Continuing Financing Activities
29 58 -26 -4.10 92 159 236 725 12 4.55 4.65
Issuance of Common Equity
37 0.94 3.77 2.59 9.02 11 20 15 13 4.62 4.65
Other Financing Activities, net
- - - -5.42 -6.56 -7.20 -8.93 -32 -0.76 -0.07 0.00
Cash Interest Paid
0.98 0.91 5.42 5.16 6.51 4.78 2.93 3.07 3.40 3.38 3.83
Cash Income Taxes Paid
0.18 0.03 0.29 0.28 -0.03 0.32 0.25 0.15 0.18 0.18 0.21

Quarterly Cash Flow Statements for NeoGenomics

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-18 -2.95 12 13 17 36 -11 23 6.91 5.02
Net Cash From Operating Activities
-16 -3.69 -13 -1.55 -5.50 18 -26 14 9.25 9.80
Net Cash From Continuing Operating Activities
-16 -3.69 -13 -1.55 -5.50 18 -26 14 9.25 9.80
Net Income / (Loss) Continuing Operations
-37 -23 -31 -24 -19 -14 -27 -19 -18 -15
Consolidated Net Income / (Loss)
-37 -23 -31 -24 -19 -14 -27 -19 -18 -15
Depreciation Expense
8.97 9.48 9.05 9.48 9.35 9.58 9.91 9.75 9.62 9.83
Amortization Expense
9.20 9.30 9.50 9.50 9.51 9.51 9.09 9.09 9.09 9.09
Non-Cash Adjustments To Reconcile Net Income
7.58 15 6.29 7.19 13 1.70 8.89 13 6.48 8.53
Changes in Operating Assets and Liabilities, net
-5.17 -14 -6.73 -3.38 -19 11 -27 0.85 1.76 -2.32
Net Cash From Investing Activities
-4.20 -1.06 24 15 21 17 15 7.31 -3.52 -5.47
Net Cash From Continuing Investing Activities
-4.20 -1.06 24 15 21 17 15 7.31 -3.52 -5.47
Purchase of Property, Plant & Equipment
-7.84 -4.53 -9.93 -7.49 -4.27 -7.06 -5.59 -13 -11 -12
Sale and/or Maturity of Investments
21 27 40 22 25 24 20 20 7.28 6.13
Net Cash From Financing Activities
2.96 1.80 1.38 0.06 1.84 1.27 0.82 1.97 1.18 0.69
Net Cash From Continuing Financing Activities
2.96 1.80 1.38 0.06 1.84 1.27 0.82 1.97 1.18 0.69
Issuance of Common Equity
3.09 1.85 1.41 0.09 1.85 1.27 0.82 1.97 1.18 0.69
Cash Interest Paid
0.00 1.26 0.43 1.26 0.43 1.26 0.43 1.26 0.45 1.69
Cash Income Taxes Paid
0.03 0.03 0.00 0.18 - - 0.09 0.09 0.14 -0.11

Annual Balance Sheets for NeoGenomics

This table presents NeoGenomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
81 351 337 344 505 710 988 1,870 1,740 1,681 1,638
Total Current Assets
59 82 79 86 104 291 449 682 605 597 596
Cash & Equivalents
34 23 13 13 9.81 173 229 317 263 342 367
Short-Term Investments
- - - - - 0.00 68 - 175 73 20
Accounts Receivable
20 49 56 60 77 94 107 112 120 131 151
Inventories, net
2.62 5.11 6.25 7.47 8.65 14 30 23 24 24 27
Prepaid Expenses
1.14 4.89 4.54 4.15 7.73 6.33 12 12 15 18 20
Other Current Assets
- - - 1.00 0.56 2.75 4.56 18 8.08 8.24 12
Plant, Property, & Equipment, net
15 35 34 37 61 64 86 109 102 92 94
Total Noncurrent Assets
7.28 234 224 222 340 355 454 1,079 1,032 992 948
Goodwill
2.93 146 147 147 198 199 211 527 523 523 523
Intangible Assets
4.21 88 77 74 140 127 121 442 408 373 340
Other Noncurrent Operating Assets
0.14 0.13 0.17 0.89 2.54 29 92 109 101 97 85
Total Liabilities & Shareholders' Equity
81 351 337 344 505 710 988 1,870 1,740 1,681 1,638
Total Liabilities
21 113 151 140 185 202 294 762 742 740 736
Total Current Liabilities
15 40 38 36 61 64 73 87 90 96 301
Short-Term Debt
3.22 14 8.73 8.99 7.87 5.00 - - - 0.00 201
Accounts Payable
6.29 12 17 10 18 20 25 18 21 20 22
Accrued Expenses
1.21 7.37 4.25 6.14 8.99 7.55 12 18 15 15 13
Current Deferred Revenue
- - - - - 1.61 4.03 5.19 7.56 2.13 0.41
Current Employee Benefit Liabilities
3.90 6.22 8.35 9.48 19 21 25 38 40 53 62
Other Current Liabilities
0.00 - - 1.41 7.23 8.81 7.81 8.02 6.65 5.61 3.38
Total Noncurrent Liabilities
6.08 73 112 103 124 138 221 674 652 643 434
Long-Term Debt
0.06 52 92 91 98 92 168 532 535 538 340
Noncurrent Deferred & Payable Income Tax Liabilities
0.82 16 15 6.69 22 16 5.42 55 35 24 22
Other Noncurrent Operating Liabilities
- - - 0.28 3.06 31 47 86 82 81 73
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
60 210 164 172 320 507 694 1,108 998 942 902
Total Preferred & Common Equity
60 210 164 172 320 507 694 1,108 998 942 902
Total Common Equity
60 210 164 172 320 507 694 1,108 998 942 902
Common Stock
80 232 216 230 340 520 701 1,124 1,161 1,190 1,228
Retained Earnings
-19 -22 -52 -58 -19 -11 -7.19 -15 -159 -247 -326
Accumulated Other Comprehensive Income / (Loss)
- - 0.00 0.27 -0.58 -1.62 0.01 -0.64 -3.90 -1.67 -0.21

Quarterly Balance Sheets for NeoGenomics

This table presents NeoGenomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
1,756 1,709 1,695 1,678 1,640 1,643 1,641
Total Current Assets
603 585 585 587 574 584 590
Cash & Equivalents
266 276 289 306 332 355 362
Short-Term Investments
177 142 120 96 53 33 26
Accounts Receivable
112 119 125 133 140 147 151
Inventories, net
24 24 25 24 20 23 24
Prepaid Expenses
17 16 17 19 19 17 18
Other Current Assets
7.52 7.62 8.43 9.32 9.31 9.16 8.31
Plant, Property, & Equipment, net
107 103 100 95 88 92 93
Total Noncurrent Assets
1,045 1,021 1,010 997 979 967 958
Goodwill
523 523 523 523 523 523 523
Intangible Assets
417 399 391 382 365 356 348
Other Noncurrent Operating Assets
106 99 97 92 91 88 87
Total Liabilities & Shareholders' Equity
1,756 1,709 1,695 1,678 1,640 1,643 1,641
Total Liabilities
743 735 739 731 717 727 733
Total Current Liabilities
85 87 95 93 77 290 296
Short-Term Debt
- - - - - 200 200
Accounts Payable
14 23 18 17 18 17 17
Accrued Expenses
20 18 18 19 18 17 23
Current Deferred Revenue
6.39 6.07 5.71 3.62 1.14 0.97 0.59
Current Employee Benefit Liabilities
38 33 46 48 35 51 52
Other Current Liabilities
6.50 6.97 7.37 6.22 4.49 3.57 3.72
Total Noncurrent Liabilities
658 648 644 638 640 437 436
Long-Term Debt
535 536 537 537 539 340 340
Noncurrent Deferred & Payable Income Tax Liabilities
38 32 29 25 23 23 23
Other Noncurrent Operating Liabilities
85 80 79 75 78 75 74
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,013 974 956 947 923 916 908
Total Preferred & Common Equity
1,013 974 956 947 923 916 908
Total Common Equity
1,013 974 956 947 923 916 908
Common Stock
1,154 1,167 1,173 1,182 1,199 1,210 1,219
Retained Earnings
-136 -190 -214 -233 -274 -293 -310
Accumulated Other Comprehensive Income / (Loss)
-5.10 -2.83 -2.57 -1.85 -1.33 -1.02 -0.64

Annual Metrics and Ratios for NeoGenomics

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - - - -
Revenue Growth
31.00% 14.62% 132.27% 3.64% 15.19% 47.73% 8.71% 8.97% 5.24% 16.07% 11.65%
EBITDA Growth
4.52% -56.05% 722.95% -10.19% 24.72% 20.75% -2.37% 20.96% -285.61% 63.03% 46.18%
EBIT Growth
-28.36% -259.85% 159.28% 34.11% 247.89% -16.69% -125.44% -368.93% -1,479.47% 32.15% 13.64%
NOPAT Growth
-34.04% -302.51% 138.24% 34.66% 241.21% 312.14% -134.29% -748.73% -32.73% 31.65% 14.51%
Net Income Growth
-44.32% -323.94% -142.29% 93.55% 766.67% 203.26% -47.89% -300.07% -1,628.17% 39.02% 10.51%
EPS Growth
-50.00% -300.00% -900.00% 65.00% 150.00% 14.29% 0.00% 0.00% 0.00% 39.66% 11.43%
Operating Cash Flow Growth
324.34% -32.35% 235.95% -16.02% 148.30% -47.82% -93.75% -1,930.34% -146.95% 97.04% 459.60%
Free Cash Flow Firm Growth
-89.55% -4,139.80% 102.88% -303.13% -654.76% 112.42% -923.80% -483.38% 88.05% 44.48% -26.82%
Invested Capital Growth
29.22% 712.77% -2.04% 6.04% 40.20% 3.50% 24.44% 109.72% -2.67% -2.81% -0.74%
Revenue Q/Q Growth
8.31% 2.34% 9.93% 5.82% 5.75% 8.03% 4.50% -0.05% 2.61% 2.93% 2.55%
EBITDA Q/Q Growth
7.13% -54.19% 46.37% 16.33% -1.34% 3.87% 58.75% -51.78% 16.84% 20.66% -3.31%
EBIT Q/Q Growth
8.13% -503.89% 632.99% 169.50% -7.60% -0.61% 83.06% -121.83% 9.26% 6.90% -0.41%
NOPAT Q/Q Growth
10.71% -2,354.36% 632.99% 169.79% -55.94% 167.80% 18.70% 12.81% 8.79% 6.76% 0.19%
Net Income Q/Q Growth
20.17% -776.00% -350.95% 96.58% -61.39% 288.08% 184.30% -117.09% 11.68% 8.68% -1.28%
EPS Q/Q Growth
0.00% -500.00% -66.67% 61.11% -22.22% 300.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
18.73% 21.59% -9.91% 49.85% 27.62% -34.10% 225.21% -2,677.86% 19.60% 91.66% -53.20%
Free Cash Flow Firm Q/Q Growth
24.10% -5,078.49% 103.03% 0.00% -979.07% 112.56% 2.60% 3.75% 18.63% 25.01% -32.33%
Invested Capital Q/Q Growth
6.44% 656.22% -0.10% 1.60% 41.02% 3.31% 2.48% -0.08% -0.79% -1.67% -0.39%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
46.76% 43.84% 42.32% 42.44% 45.99% 48.15% 41.83% 38.62% 36.86% 41.34% 43.92%
EBITDA Margin
9.17% 3.51% 12.45% 10.79% 11.68% 9.55% 8.58% 9.52% -16.79% -5.35% -2.58%
Operating Margin
2.55% -5.65% 0.93% 1.21% 3.63% 3.18% -3.15% -24.52% -30.92% -18.21% -13.94%
EBIT Margin
2.61% -3.64% 0.93% 1.20% 3.63% 2.05% -0.48% -2.06% -30.96% -18.10% -14.00%
Profit (Net Income) Margin
1.30% -2.54% -2.65% -0.16% 0.95% 1.96% 0.94% -1.72% -28.30% -14.87% -11.92%
Tax Burden Percent
87.82% 56.47% 78.31% 14.94% 69.04% 219.64% -29.68% 55.37% 90.53% 90.60% 97.58%
Interest Burden Percent
56.68% 123.49% -363.94% -91.70% 38.03% 43.52% 659.60% 150.86% 100.95% 90.67% 87.23%
Effective Tax Rate
12.18% 0.00% 0.00% 0.00% 30.96% -119.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
6.24% -2.46% 0.53% 0.70% 1.94% 6.74% -2.02% -10.00% -9.94% -6.98% -6.08%
ROIC Less NNEP Spread (ROIC-NNEP)
14.53% 9.94% -10.27% -1.90% -2.60% -198.82% -13.97% -116.38% -69.21% -18.38% -16.36%
Return on Net Nonoperating Assets (RNNOA)
-3.48% 0.76% -3.43% -0.91% -0.94% -4.80% 2.72% 9.08% -3.76% -2.09% -2.46%
Return on Equity (ROE)
2.76% -1.70% -2.89% -0.20% 1.01% 1.93% 0.69% -0.93% -13.70% -9.07% -8.54%
Cash Return on Invested Capital (CROIC)
-19.25% -158.63% 2.59% -5.16% -31.53% 3.30% -23.80% -80.86% -7.23% -4.13% -5.33%
Operating Return on Assets (OROA)
3.76% -1.68% 0.63% 0.85% 2.37% 1.38% -0.25% -0.70% -8.74% -6.26% -5.57%
Return on Assets (ROA)
1.87% -1.17% -1.78% -0.12% 0.62% 1.32% 0.49% -0.58% -7.99% -5.14% -4.74%
Return on Common Equity (ROCE)
2.76% -1.54% -2.54% -0.17% 0.94% 1.93% 0.69% -0.93% -13.70% -9.07% -8.54%
Return on Equity Simple (ROE_SIMPLE)
1.87% -1.21% -3.75% -0.23% 0.82% 1.58% 0.60% -0.75% -14.45% -9.34% -8.72%
Net Operating Profit after Tax (NOPAT)
1.95 -3.94 1.51 2.03 6.93 29 -9.79 -83 -110 -75 -64
NOPAT Margin
2.24% -3.95% 0.65% 0.85% 2.50% 6.99% -2.20% -17.16% -21.65% -12.75% -9.76%
Net Nonoperating Expense Percent (NNEP)
-8.29% -12.39% 10.81% 2.61% 4.55% 205.56% 11.94% 106.37% 59.28% 11.39% 10.28%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -7.20% -5.10% -4.47%
Cost of Revenue to Revenue
53.24% 56.16% 57.68% 57.56% 54.01% 51.85% 58.17% 61.38% 63.14% 58.66% 56.08%
SG&A Expenses to Revenue
27.34% 33.70% 27.58% 29.29% 30.65% 31.31% 32.35% 45.70% 47.74% 41.09% 39.32%
R&D to Revenue
3.09% 4.21% 2.01% 1.51% 1.08% 2.08% 1.85% 4.52% 5.95% 4.62% 4.72%
Operating Expenses to Revenue
44.21% 49.49% 41.39% 41.23% 42.36% 44.96% 44.97% 63.14% 67.79% 59.55% 57.86%
Earnings before Interest and Taxes (EBIT)
2.27 -3.64 2.16 2.89 10 8.38 -2.13 -9.99 -158 -107 -92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
7.98 3.51 29 26 32 39 38 46 -86 -32 -17
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.14 2.27 4.11 4.14 3.66 6.02 8.61 3.79 1.17 2.19 2.34
Price to Tangible Book Value (P/TBV)
4.70 0.00 0.00 0.00 0.00 16.76 16.49 30.26 17.42 45.19 53.03
Price to Revenue (P/Rev)
2.87 4.76 2.90 2.97 4.24 7.47 13.45 8.67 2.29 3.49 3.20
Price to Earnings (P/E)
220.92 0.00 0.00 0.00 192.66 381.45 1,432.85 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.45% 0.00% 0.00% 0.00% 0.52% 0.26% 0.07% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
6.39 1.93 2.82 2.82 3.05 6.91 10.85 3.92 1.15 2.05 2.15
Enterprise Value to Revenue (EV/Rev)
2.58 5.53 3.41 3.49 4.59 7.28 13.10 9.12 2.48 3.69 3.44
Enterprise Value to EBITDA (EV/EBITDA)
28.18 157.26 27.35 32.32 39.26 76.28 152.71 95.80 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
98.89 0.00 366.30 289.84 126.23 355.51 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
115.45 0.00 523.28 412.35 183.10 104.24 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
23.80 86.27 36.75 46.44 28.34 127.42 3,986.40 0.00 0.00 0.00 323.17
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 107.55 0.00 0.00 212.99 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.14 0.30 0.57 0.52 0.33 0.19 0.24 0.48 0.54 0.57 0.60
Long-Term Debt to Equity
0.09 0.24 0.52 0.47 0.31 0.18 0.24 0.48 0.54 0.57 0.38
Financial Leverage
-0.24 0.08 0.33 0.48 0.36 0.02 -0.19 -0.08 0.05 0.11 0.15
Leverage Ratio
1.47 1.45 1.62 1.74 1.62 1.47 1.41 1.59 1.71 1.76 1.80
Compound Leverage Factor
0.84 1.79 -5.90 -1.60 0.62 0.64 9.32 2.39 1.73 1.60 1.57
Debt to Total Capital
12.31% 23.06% 36.26% 34.01% 24.86% 16.03% 19.49% 32.45% 34.91% 36.37% 37.49%
Short-Term Debt to Total Capital
4.68% 4.52% 2.98% 2.90% 1.85% 0.83% 0.00% 0.00% 0.00% 0.00% 13.91%
Long-Term Debt to Total Capital
7.63% 18.54% 33.28% 31.11% 23.01% 15.20% 19.49% 32.45% 34.91% 36.37% 23.58%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 9.24% 7.81% 10.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
87.69% 67.70% 55.92% 55.47% 75.14% 83.98% 80.51% 67.55% 65.09% 63.63% 62.51%
Debt to EBITDA
1.06 20.35 3.68 4.07 3.28 2.48 4.41 11.55 -6.26 -17.01 -31.79
Net Debt to EBITDA
-3.16 13.68 3.24 3.57 2.98 -1.95 -4.14 4.68 -1.14 -3.89 -9.06
Long-Term Debt to EBITDA
0.66 16.36 3.38 3.72 3.04 2.35 4.41 11.55 -6.26 -17.01 -19.99
Debt to NOPAT
4.35 -18.10 70.38 51.90 15.29 3.39 -17.16 -6.41 -4.85 -7.14 -8.39
Net Debt to NOPAT
-12.94 -12.16 62.08 45.59 13.88 -2.67 16.10 -2.59 -0.88 -1.63 -2.39
Long-Term Debt to NOPAT
2.70 -14.55 64.59 47.47 14.16 3.21 -17.16 -6.41 -4.85 -7.14 -5.28
Altman Z-Score
8.73 2.82 3.32 3.72 4.47 10.04 13.09 3.92 1.16 1.97 1.88
Noncontrolling Interest Sharing Ratio
0.00% 9.58% 12.12% 14.19% 6.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.02 2.06 2.07 2.35 1.70 4.55 6.13 7.81 6.73 6.20 1.98
Quick Ratio
3.70 1.81 1.79 2.01 1.42 4.18 5.51 4.92 6.20 5.67 1.78
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-6.01 -255 7.34 -15 -113 14 -115 -672 -80 -45 -57
Operating Cash Flow to CapEx
250.53% 288.62% 284.99% 131.75% 312.97% 116.68% 5.02% -41.66% -351.16% -6.79% 17.10%
Free Cash Flow to Firm to Interest Expense
-6.10 -298.38 0.73 -2.69 -18.06 2.96 -9.66 -81.74 -10.60 -6.46 -8.55
Operating Cash Flow to Interest Expense
9.59 7.49 2.15 3.26 7.19 4.94 0.12 -3.25 -8.71 -0.28 1.06
Operating Cash Flow Less CapEx to Interest Expense
5.76 4.89 1.39 0.78 4.89 0.71 -2.32 -11.05 -11.18 -4.45 -5.14
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.44 0.46 0.67 0.71 0.65 0.67 0.52 0.34 0.28 0.35 0.40
Accounts Receivable Turnover
4.45 2.88 4.44 4.14 4.03 4.78 4.42 4.42 4.40 4.72 4.69
Inventory Turnover
18.86 14.51 23.54 20.15 18.54 18.39 11.77 11.23 13.50 14.33 14.56
Fixed Asset Turnover
7.03 4.02 6.76 6.81 5.68 6.54 5.92 4.96 4.81 6.08 7.10
Accounts Payable Turnover
8.85 5.98 9.14 10.16 10.59 11.35 11.61 13.86 16.75 16.99 17.67
Days Sales Outstanding (DSO)
82.01 126.94 82.24 88.07 90.57 76.41 82.57 82.51 83.01 77.41 77.85
Days Inventory Outstanding (DIO)
19.36 25.15 15.51 18.11 19.69 19.85 31.01 32.49 27.03 25.47 25.08
Days Payable Outstanding (DPO)
41.22 61.08 39.92 35.94 34.47 32.15 31.43 26.33 21.79 21.48 20.66
Cash Conversion Cycle (CCC)
60.15 91.01 57.82 70.25 75.80 64.10 82.14 88.67 88.25 81.40 82.26
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
35 286 280 297 417 431 537 1,125 1,095 1,065 1,057
Invested Capital Turnover
2.79 0.62 0.82 0.83 0.78 0.96 0.92 0.58 0.46 0.55 0.62
Increase / (Decrease) in Invested Capital
7.96 251 -5.83 17 119 15 105 589 -30 -31 -7.93
Enterprise Value (EV)
225 552 789 838 1,269 2,978 5,820 4,417 1,264 2,185 2,270
Market Capitalization
250 475 673 712 1,173 3,054 5,978 4,201 1,167 2,062 2,115
Book Value per Share
$1.01 $3.47 $2.09 $2.14 $3.45 $4.86 $6.25 $9.00 $7.90 $7.39 $7.03
Tangible Book Value per Share
$0.89 ($0.41) ($0.77) ($0.61) ($0.19) $1.74 $3.27 $1.13 $0.53 $0.36 $0.31
Total Capital
69 309 293 310 426 604 862 1,641 1,533 1,480 1,443
Total Debt
8.48 71 106 105 106 97 168 532 535 538 541
Total Long-Term Debt
5.26 57 97 96 98 92 168 532 535 538 340
Net Debt
-25 48 94 93 96 -76 -158 216 97 123 154
Capital Expenditures (CapEx)
3.77 2.22 7.54 14 14 20 29 64 19 29 41
Debt-free, Cash-free Net Working Capital (DFCFNWC)
14 33 37 46 41 59 79 277 77 85 109
Debt-free Net Working Capital (DFNWC)
47 56 49 58 51 232 376 594 515 501 496
Net Working Capital (NWC)
44 42 41 49 43 227 376 594 515 501 295
Net Nonoperating Expense (NNE)
0.82 -1.41 7.65 2.43 4.29 21 -14 -75 34 13 14
Net Nonoperating Obligations (NNO)
-25 48 94 93 96 -76 -158 17 97 123 154
Total Depreciation and Amortization (D&A)
5.71 7.14 27 23 22 31 40 56 72 75 75
Debt-free, Cash-free Net Working Capital to Revenue
15.68% 32.95% 15.93% 18.97% 14.74% 14.39% 17.84% 57.29% 15.18% 14.42% 16.46%
Debt-free Net Working Capital to Revenue
54.37% 56.42% 21.33% 24.31% 18.29% 56.71% 84.50% 122.70% 101.10% 84.60% 75.02%
Net Working Capital to Revenue
50.67% 42.39% 17.56% 20.56% 15.45% 55.48% 84.50% 122.70% 101.10% 84.60% 44.63%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.02 $0.00 ($0.39) $0.00 $0.07 $0.08 $0.04 ($0.07) $0.00 $0.00 ($0.62)
Adjusted Weighted Average Basic Shares Outstanding
53.48M 0.00 77.54M 79.43M 85.62M 100.47M 108.58M 119.96M 124.22M 125.50M 126.66M
Adjusted Diluted Earnings per Share
$0.02 $0.00 ($0.39) $0.00 $0.07 $0.08 $0.04 ($0.07) $0.00 $0.00 ($0.62)
Adjusted Weighted Average Diluted Shares Outstanding
56.02M 0.00 77.54M 79.43M 91.57M 103.62M 111.79M 119.96M 124.22M 125.50M 126.66M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
60.26M 0.00 78.82M 80.51M 94.57M 104.83M 116.94M 124.03M 127.46M 127.61M 128.46M
Normalized Net Operating Profit after Tax (NOPAT)
1.95 -3.94 3.93 2.03 6.93 9.10 -9.79 -83 -107 -68 -60
Normalized NOPAT Margin
2.24% -3.95% 1.70% 0.85% 2.50% 2.23% -2.20% -17.16% -21.03% -11.43% -9.05%
Pre Tax Income Margin
1.48% -4.50% -3.38% -1.10% 1.38% 0.89% -3.16% -3.11% -31.26% -16.41% -12.21%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
2.31 -4.26 0.22 0.52 1.61 1.77 -0.18 -1.22 -20.82 -15.50 -13.98
NOPAT to Interest Expense
1.98 -4.62 0.15 0.37 1.11 6.04 -0.82 -10.11 -14.55 -10.92 -9.74
EBIT Less CapEx to Interest Expense
-1.52 -6.85 -0.54 -1.95 -0.68 -2.46 -2.62 -9.02 -23.30 -19.67 -20.18
NOPAT Less CapEx to Interest Expense
-1.85 -7.21 -0.60 -2.10 -1.18 1.80 -3.26 -17.92 -17.03 -15.08 -15.95
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for NeoGenomics

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
6.13% 10.32% 17.11% 17.47% 17.99% 12.15% 13.86% 11.97% 10.44% 10.57%
EBITDA Growth
-371.48% 69.50% 51.44% 54.48% 74.49% 108.32% 28.86% 69.48% 60.18% -86.10%
EBIT Growth
-80.51% 37.91% 32.15% 27.28% 38.48% 30.07% 12.38% 24.76% 14.04% -2.07%
NOPAT Growth
0.51% 36.53% 32.59% 24.70% 38.76% 29.60% 12.85% 26.60% 12.39% 0.93%
Net Income Growth
-81.11% 45.67% 37.67% 31.08% 49.76% 36.85% 12.13% 23.38% 4.41% -6.97%
EPS Growth
-76.47% 0.00% 37.50% 0.00% 50.00% 0.00% 16.00% 0.00% 6.67% 0.00%
Operating Cash Flow Growth
-109.50% 81.37% 56.29% 90.89% 66.22% 582.61% -104.18% 997.42% 268.20% -44.89%
Free Cash Flow Firm Growth
99.14% 101.87% 101.55% 121.98% 183.01% 54.36% -165.60% -91.88% 56.74% -127.81%
Invested Capital Growth
-1.98% -2.67% -3.03% -2.51% -1.94% -2.81% -1.38% -1.47% -2.02% -0.74%
Revenue Q/Q Growth
2.97% 7.71% -1.07% 7.07% 3.43% 2.37% 0.44% 5.29% 2.02% 2.49%
EBITDA Q/Q Growth
4.79% 64.32% -118.85% 38.78% 46.63% 111.64% -1,970.14% 73.74% 30.36% 104.06%
EBIT Q/Q Growth
1.55% 33.18% -33.36% 17.12% 16.71% 24.05% -67.10% 28.83% 4.84% 9.81%
NOPAT Q/Q Growth
0.48% 33.22% -32.94% 14.77% 19.06% 23.23% -64.57% 28.22% 3.39% 13.19%
Net Income Q/Q Growth
-4.39% 38.44% -35.74% 20.99% 23.90% 22.63% -88.89% 31.11% 5.06% 13.42%
EPS Q/Q Growth
-7.14% 40.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
4.26% 77.35% -244.42% 87.80% -255.10% 423.52% -245.72% 153.61% -33.44% 5.99%
Free Cash Flow Firm Q/Q Growth
82.90% 313.85% -16.61% -27.95% -35.40% 297.68% -135.44% 108.92% 1,146.96% -170.55%
Invested Capital Q/Q Growth
-0.67% -0.79% -0.25% -0.82% -0.09% -1.67% 1.22% -0.91% -0.65% -0.39%
Profitability Metrics
- - - - - - - - - -
Gross Margin
37.97% 40.97% 39.95% 40.77% 41.01% 43.45% 41.90% 44.07% 44.62% 44.92%
EBITDA Margin
-16.55% -5.48% -12.13% -6.93% -3.58% 0.41% -7.58% -1.89% -1.29% 0.05%
Operating Margin
-30.68% -19.02% -25.56% -20.35% -15.92% -11.94% -19.56% -13.34% -12.63% -10.70%
EBIT Margin
-30.66% -19.02% -25.64% -19.85% -15.99% -11.86% -19.73% -13.34% -12.44% -10.95%
Profit (Net Income) Margin
-28.62% -16.36% -22.44% -16.56% -12.19% -9.21% -17.32% -11.33% -10.55% -8.91%
Tax Burden Percent
93.00% 88.89% 91.33% 91.33% 86.32% 93.72% 97.76% 98.03% 99.16% 95.01%
Interest Burden Percent
100.35% 96.74% 95.83% 91.35% 88.31% 82.85% 89.79% 86.67% 85.48% 85.64%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-9.57% -6.11% -8.54% -7.16% -5.86% -4.58% -7.71% -5.45% -5.31% -4.66%
ROIC Less NNEP Spread (ROIC-NNEP)
-32.51% -13.49% -15.89% -10.64% -7.26% -5.78% -11.87% -7.81% -7.30% -6.43%
Return on Net Nonoperating Assets (RNNOA)
-1.21% -0.73% -1.32% -1.04% -0.84% -0.66% -1.70% -1.16% -1.13% -0.97%
Return on Equity (ROE)
-10.78% -6.84% -9.86% -8.20% -6.70% -5.24% -9.41% -6.62% -6.45% -5.63%
Cash Return on Invested Capital (CROIC)
-8.85% -7.23% -5.79% -5.81% -5.44% -4.13% -5.27% -4.72% -3.99% -5.33%
Operating Return on Assets (OROA)
-8.32% -5.37% -7.68% -6.28% -5.35% -4.10% -7.20% -5.02% -4.83% -4.36%
Return on Assets (ROA)
-7.76% -4.62% -6.72% -5.24% -4.08% -3.19% -6.32% -4.27% -4.09% -3.55%
Return on Common Equity (ROCE)
-10.78% -6.84% -9.86% -8.20% -6.70% -5.24% -9.41% -6.62% -6.45% -5.63%
Return on Equity Simple (ROE_SIMPLE)
-16.12% 0.00% -12.89% -11.99% -10.17% 0.00% -9.12% -8.58% -8.56% 0.00%
Net Operating Profit after Tax (NOPAT)
-28 -18 -25 -21 -17 -13 -21 -15 -15 -13
NOPAT Margin
-21.48% -13.31% -17.89% -14.24% -11.15% -8.36% -13.69% -9.34% -8.84% -7.49%
Net Nonoperating Expense Percent (NNEP)
22.95% 7.37% 7.35% 3.49% 1.40% 1.20% 4.16% 2.35% 1.99% 1.76%
Return On Investment Capital (ROIC_SIMPLE)
- -1.20% - - - -0.88% - - - -0.89%
Cost of Revenue to Revenue
62.03% 59.03% 60.05% 59.23% 58.99% 56.55% 58.10% 55.93% 55.38% 55.08%
SG&A Expenses to Revenue
49.92% 39.56% 44.85% 41.05% 40.46% 38.42% 42.11% 38.50% 39.90% 37.00%
R&D to Revenue
5.68% 4.81% 5.39% 5.11% 3.48% 4.58% 4.88% 4.79% 4.58% 4.63%
Operating Expenses to Revenue
68.65% 59.99% 65.51% 61.11% 56.93% 55.39% 61.47% 57.41% 57.25% 55.62%
Earnings before Interest and Taxes (EBIT)
-39 -26 -35 -29 -24 -18 -31 -22 -21 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-21 -7.60 -17 -10 -5.44 0.63 -12 -3.11 -2.17 0.09
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.07 1.17 2.28 2.14 1.66 2.19 2.17 1.93 2.08 2.34
Price to Tangible Book Value (P/TBV)
14.76 17.42 42.49 47.98 36.70 45.19 55.85 48.25 50.54 53.03
Price to Revenue (P/Rev)
2.18 2.29 4.19 3.72 2.73 3.49 3.28 2.82 2.93 3.20
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.06 1.15 2.14 2.01 1.57 2.05 2.00 1.80 1.93 2.15
Enterprise Value to Revenue (EV/Rev)
2.36 2.48 4.41 3.95 2.96 3.69 3.53 3.06 3.17 3.44
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 7,284.70 136.13 323.17
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.53 0.54 0.55 0.56 0.57 0.57 0.58 0.59 0.60 0.60
Long-Term Debt to Equity
0.53 0.54 0.55 0.56 0.57 0.57 0.58 0.37 0.37 0.38
Financial Leverage
0.04 0.05 0.08 0.10 0.12 0.11 0.14 0.15 0.16 0.15
Leverage Ratio
1.70 1.71 1.73 1.74 1.75 1.76 1.76 1.78 1.79 1.80
Compound Leverage Factor
1.71 1.66 1.65 1.59 1.55 1.46 1.58 1.55 1.53 1.54
Debt to Total Capital
34.54% 34.91% 35.49% 35.95% 36.20% 36.37% 36.85% 37.08% 37.30% 37.49%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.75% 13.84% 13.91%
Long-Term Debt to Total Capital
34.54% 34.91% 35.49% 35.95% 36.20% 36.37% 36.85% 23.33% 23.47% 23.58%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
65.46% 65.09% 64.51% 64.05% 63.80% 63.63% 63.15% 62.92% 62.70% 62.51%
Debt to EBITDA
-5.20 -6.26 -7.89 -9.63 -13.48 -17.01 -20.09 -27.32 -32.79 -31.79
Net Debt to EBITDA
-0.89 -1.14 -1.74 -2.29 -3.39 -3.89 -5.74 -7.69 -9.26 -9.06
Long-Term Debt to EBITDA
-5.20 -6.26 -7.89 -9.63 -13.48 -17.01 -20.09 -17.19 -20.63 -19.99
Debt to NOPAT
-4.42 -4.85 -5.44 -5.86 -6.65 -7.14 -7.46 -8.09 -8.37 -8.39
Net Debt to NOPAT
-0.75 -0.88 -1.20 -1.39 -1.67 -1.63 -2.13 -2.28 -2.36 -2.39
Long-Term Debt to NOPAT
-4.42 -4.85 -5.44 -5.86 -6.65 -7.14 -7.46 -5.09 -5.26 -5.28
Altman Z-Score
1.33 1.41 2.25 2.10 1.74 2.14 2.12 1.76 1.85 2.03
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
7.10 6.73 6.75 6.16 6.32 6.20 7.48 2.01 1.99 1.98
Quick Ratio
6.54 6.20 6.20 5.64 5.76 5.67 6.85 1.84 1.82 1.78
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-5.40 12 9.63 6.94 4.48 18 -6.32 0.56 7.02 -4.96
Operating Cash Flow to CapEx
-207.45% -81.27% -127.85% -20.66% -128.61% 252.01% -464.01% 106.22% 85.62% 84.49%
Free Cash Flow to Firm to Interest Expense
-38.84 2.21 5.48 3.89 2.66 10.60 -3.75 0.34 4.28 -3.05
Operating Cash Flow to Interest Expense
-117.06 -0.71 -7.22 -0.87 -3.26 10.58 -15.38 8.34 5.63 6.03
Operating Cash Flow Less CapEx to Interest Expense
-173.50 -1.58 -12.87 -5.07 -5.80 6.38 -18.69 0.49 -0.95 -1.11
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.27 0.28 0.30 0.32 0.33 0.35 0.36 0.38 0.39 0.40
Accounts Receivable Turnover
4.58 4.40 4.61 4.66 4.70 4.72 4.71 4.62 4.54 4.69
Inventory Turnover
14.04 13.50 13.48 14.15 14.25 14.33 15.88 14.97 14.99 14.56
Fixed Asset Turnover
4.64 4.81 5.00 5.22 5.71 6.08 6.40 6.54 6.87 7.10
Accounts Payable Turnover
15.17 16.75 15.06 19.06 22.34 16.99 17.32 20.54 21.82 17.67
Days Sales Outstanding (DSO)
79.71 83.01 79.11 78.31 77.67 77.41 77.44 79.02 80.49 77.85
Days Inventory Outstanding (DIO)
25.99 27.03 27.08 25.79 25.61 25.47 22.98 24.39 24.34 25.08
Days Payable Outstanding (DPO)
24.06 21.79 24.23 19.15 16.34 21.48 21.08 17.77 16.73 20.66
Cash Conversion Cycle (CCC)
81.64 88.25 81.96 84.95 86.95 81.40 79.34 85.63 88.10 82.26
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
1,104 1,095 1,093 1,084 1,083 1,065 1,078 1,068 1,061 1,057
Invested Capital Turnover
0.45 0.46 0.48 0.50 0.53 0.55 0.56 0.58 0.60 0.62
Increase / (Decrease) in Invested Capital
-22 -30 -34 -28 -21 -31 -15 -16 -22 -7.93
Enterprise Value (EV)
1,174 1,264 2,337 2,178 1,704 2,185 2,158 1,923 2,043 2,270
Market Capitalization
1,083 1,167 2,219 2,050 1,569 2,062 2,004 1,771 1,890 2,115
Book Value per Share
$8.05 $7.90 $7.65 $7.50 $7.43 $7.39 $7.32 $7.17 $7.09 $7.03
Tangible Book Value per Share
$0.58 $0.53 $0.41 $0.34 $0.34 $0.36 $0.28 $0.29 $0.29 $0.31
Total Capital
1,548 1,533 1,510 1,493 1,485 1,480 1,462 1,456 1,449 1,443
Total Debt
535 535 536 537 537 538 539 540 540 541
Total Long-Term Debt
535 535 536 537 537 538 539 340 340 340
Net Debt
91 97 118 127 135 123 154 152 153 154
Capital Expenditures (CapEx)
7.84 4.53 9.93 7.49 4.27 7.06 5.59 13 11 12
Debt-free, Cash-free Net Working Capital (DFCFNWC)
75 77 80 81 92 85 112 106 106 109
Debt-free Net Working Capital (DFNWC)
518 515 498 490 494 501 497 494 494 496
Net Working Capital (NWC)
518 515 498 490 494 501 497 294 294 295
Net Nonoperating Expense (NNE)
9.20 4.22 6.24 3.41 1.58 1.32 5.66 3.28 2.86 2.44
Net Nonoperating Obligations (NNO)
91 97 118 127 135 123 154 152 153 154
Total Depreciation and Amortization (D&A)
18 19 19 19 19 19 19 19 19 19
Debt-free, Cash-free Net Working Capital to Revenue
15.06% 15.18% 15.19% 14.60% 15.96% 14.42% 18.40% 16.95% 16.53% 16.46%
Debt-free Net Working Capital to Revenue
104.35% 101.10% 94.08% 88.81% 85.95% 84.60% 81.42% 78.68% 76.73% 75.02%
Net Working Capital to Revenue
104.35% 101.10% 94.08% 88.81% 85.95% 84.60% 81.42% 46.84% 45.62% 44.63%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.30) ($0.18) ($0.25) ($0.19) ($0.15) $0.00 ($0.21) $0.00 ($0.14) $0.00
Adjusted Weighted Average Basic Shares Outstanding
124.43M 124.22M 125.03M 125.36M 125.69M 125.50M 126.11M 126.41M 126.95M 126.66M
Adjusted Diluted Earnings per Share
($0.30) ($0.18) ($0.25) ($0.19) ($0.15) $0.00 ($0.21) $0.00 ($0.14) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
124.43M 124.22M 125.03M 125.36M 125.69M 125.50M 126.11M 126.41M 126.95M 126.66M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
126.30M 127.46M 127.58M 127.55M 127.47M 127.61M 127.71M 128.16M 128.36M 128.46M
Normalized Net Operating Profit after Tax (NOPAT)
-28 -15 -21 -19 -15 -12 -20 -14 -14 -12
Normalized NOPAT Margin
-21.48% -11.04% -15.50% -12.78% -10.17% -7.82% -12.62% -8.68% -8.42% -6.79%
Pre Tax Income Margin
-30.77% -18.40% -24.57% -18.13% -14.12% -9.83% -17.72% -11.56% -10.64% -9.38%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-284.06 -5.06 -20.03 -16.35 -14.42 -10.98 -18.30 -13.17 -12.72 -11.60
NOPAT to Interest Expense
-198.97 -3.54 -13.97 -11.73 -10.05 -7.73 -12.70 -9.22 -9.04 -7.93
EBIT Less CapEx to Interest Expense
-340.50 -5.93 -25.68 -20.55 -16.95 -15.17 -21.61 -21.02 -19.29 -18.74
NOPAT Less CapEx to Interest Expense
-255.40 -4.41 -19.62 -15.93 -12.59 -11.93 -16.01 -17.07 -15.61 -15.07
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About NeoGenomics' Financials

When does NeoGenomics's fiscal year end?

According to the most recent income statement we have on file, NeoGenomics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has NeoGenomics' net income changed over the last 10 years?

NeoGenomics' net income appears to be on an upward trend, with a most recent value of -$78.73 million in 2024, falling from $1.13 million in 2014. The previous period was -$87.97 million in 2023.

What is NeoGenomics's operating income?
NeoGenomics's total operating income in 2024 was -$92.11 million, based on the following breakdown:
  • Total Gross Profit: $290.10 million
  • Total Operating Expenses: $382.21 million
How has NeoGenomics revenue changed over the last 10 years?

Over the last 10 years, NeoGenomics' total revenue changed from $87.07 million in 2014 to $660.57 million in 2024, a change of 658.7%.

How much debt does NeoGenomics have?

NeoGenomics' total liabilities were at $735.70 million at the end of 2024, a 0.5% decrease from 2023, and a 3,453.9% increase since 2014.

How much cash does NeoGenomics have?

In the past 10 years, NeoGenomics' cash and equivalents has ranged from $9.81 million in 2018 to $367.01 million in 2024, and is currently $367.01 million as of their latest financial filing in 2024.

How has NeoGenomics' book value per share changed over the last 10 years?

Over the last 10 years, NeoGenomics' book value per share changed from 1.01 in 2014 to 7.03 in 2024, a change of 597.9%.



This page (NASDAQ:NEO) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners